Endometriosis

PinkDx announced an IJGC publication of data that demonstrated signals associated with endometrial cancer can be detected from a vaginal swab.

Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Alla Vash-Margita, MD, FACOG, details how identifying differentially expressed microRNAs in 13- to 26-year-olds could provide a pathway for early detection of endometriosis.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ENDO-205 is EndoCyclic Therapeutics' lead program and consists of a first-in-class, non-hormonal targeted epeptide therapeutic for endometriosis, according to the company.

Flo Health chief medical officer Anna Klepchukova and study investigator Erica Stockwell highlight the benefits of digital symptom checkers for endometriosis.

Among a survey of over 800 providers, menopause care was the top area for expected greatest improvement over the next 5 years.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Yale's Alessandro Santin, MD, emphasizes that "knowing our enemy" through sequencing is a way to identify targetable pathways for rare and aggressive ESS cases.

Alessandro Santin, MD, highlights how POLE and mismatch repair mutations in high-grade ESS create a clinical opportunity for using immune checkpoint inhibitors.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

"It's only when you acquire the type of deep knowledge in the molecular characteristic that you may really identify potential targets," said study investigator Alessandro Santin, MD.

The Menopause Society reported new data from 68 health organizations that showed vaginal estrogen therapy does not elevate recurrence risk in survivors aged 18 to 51.

Data published in npj Digital Medicine indicates that digital symptom checkers for endometriosis can reduce diagnostic delay by over 4 years and save more than $5,000 per patient.